US Supreme Court preserves access to abortion drug, Mifepristone

The US Supreme Court has preserved access to a commonly used abortion pill, ruling the drug can remain available while a legal case continues, the BBC reports.

In a split decision, it also rejected restrictions on mifepristone implemented by a lower court, essentially maintaining the status quo.

The future of the drug was called into question after a Texas judge sought to invalidate its long-standing approval.

The case could have wide-ranging implications for abortion access.

Mifepristone is part of a two-drug regimen that now accounts for more than half of abortions in the country. It has been used by more than five million women in the US to end their pregnancies.

It was first approved by the US Food and Drug Administration (FDA) more than 20 years ago after four years of review.

It comes after the Supreme Court – which has a 6-3 conservative majority – overturned Roe v Wade in June last year, ending the nationwide guarantee to abortion and giving states the power to ban the procedure.

With Friday’s ruling, the mifepristone case now returns to the lower 5th Circuit Court of Appeals.

It is likely that the case will come before the Supreme Court once again, setting up the most significant ruling on the issue of abortion since Roe was overturned.

The FDA also placed mifepristone in a category of 60 drugs that are regulated under a system of extra restrictions and regular evaluations.

Mainstream medical organisations, including the American College of Obstetrics and Gynaecologists and the World Health Organization, have said the abortion pill is safe and effective.

But earlier this month, Texas court judge Matthew Kacsmaryk ruled to suspend the FDA approval of mifepristone, saying the agency had violated federal rules that allowed for the accelerated approval of some drugs, and had erred in its scientific assessment of the drug.

Judge Kacsmaryk’s preliminary decision came after a group of anti-abortion health professionals launched a case challenging the safety of mifepristone.

His 7 April ruling was made just minutes before a decision from a judge in Washington state ordered the FDA to make no change to the drug’s availability and preserved access to mifepristone in 17 US states.

US President Joe Biden’s administration appealed the Texas ruling and asked for the Texas court’s order to be placed on hold.

A divided appeals court said mifepristone could remain available, but with certain restrictions, while the appeal was underway.

Among the restrictions imposed by the 5th Circuit Court of Appeals was a limit on sending the pills by mail, effectively requiring in-person visits. These restrictions have now been overturned by the Supreme Court, for now.

Although a full vote breakdown was not released, BBC reports that two of the Supreme Court’s conservative members, Justice Clarence Thomas and Justice Samuel Alito, dissented publicly from the decision, which came in a single paragraph, issued hours before a self-imposed deadline.

Justice Thomas provided no reasons for his dissent, while Justice Alito wrote that the Supreme Court has been criticised in the past for issuing emergency orders, called the “shadow docket” by critics.

 

READ ALSO FROM NIGERIAN TRIBUNE 

• One year after, Alaafin’s first son tells story of late king’s last moments in hospital

• Overcrowding: Lagos passengers cram inside train’s toilets as fare jumps by 35%

• ‘My husband locked me up in the room, made me beg to eat’

• Man drags sex partner to court for sending him her nude photos

• SOS: That unsuccessful Adamawa prowl…

• 2023 UTME: JAMB asks candidates to print examination notification slips